3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
128
Carboplatin
126
Pemetrexed
106
Cisplatin
79
Paclitaxel
60
osimertinib
54
Nivolumab
53
Docetaxel
52
durvalumab
48
Specimen Handling
40
Magnetic Resonance Spectroscopy
36
Gemcitabine
36
Radiosurgery
29
atezolizumab
27
130-nm albumin-bound paclitaxel
27
Cetuximab
26
Radiotherapy
23
Ipilimumab
22
Drug Therapy
22
cemiplimab
20
Bevacizumab
20
amivantamab
18
Taxes
16
Ramucirumab
13
tislelizumab
12
alectinib
12
Radiation
12
Biopsy
12
lazertinib
11
Oxaliplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
tisotumab vedotin
×
90 days
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled